Antibody Class Switch Recombination: Swapping IgM for IgG, IgA, and IgE

What class switch recombination is and where it happens

Class switch recombination is a programmed, irreversible DNA rearrangement that changes an antibody's heavy-chain constant region — and therefore its class or isotype — while leaving the antigen-binding variable domain intact. It occurs in mature B lymphocytes only after they are activated, chiefly inside the germinal centers of lymph nodes, spleen, and mucosal tissue, during a T-cell-dependent immune response.

The relevant DNA lives at the immunoglobulin heavy-chain (IGH) locus, on human chromosome 14q32 (mouse chromosome 12). Downstream of the rearranged V(D)J exon sit the constant-region genes in a fixed order: Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a/Cγ2c, Cε, Cα (mouse order shown; human order differs slightly but follows the same logic). A naive B cell transcribes Cμ first and so makes IgM. CSR physically deletes the intervening DNA — up to ~200 kb — to bring a new constant gene (Cγ, Cε, or Cα) directly behind the same V(D)J exon.

• Key requirement: two activation signals — CD40-CD40L engagement (or TLR ligands) plus specific cytokines that choose the target isotype.

The mechanism, step by step

CSR is deletional recombination between two repetitive switch (S) regions — 1-10 kb of G-rich, palindromic tandem repeats sitting upstream of each constant gene (Sμ, Sγ, Sε, Sα). The choreography:

• 1. Germline transcription. Cytokines open a specific downstream S region by driving transcription from an intronic (I) promoter through the S region. The nascent transcript loops back on the template strand, leaving the non-template strand single-stranded as an R-loop — the substrate AID needs.
• 2. Deamination. AID (activation-induced cytidine deaminase) deaminates cytosine to uracil (C-to-U) on the exposed single-stranded DNA of both the donor Sμ and an acceptor S region.
• 3. Lesion processing. UNG (uracil-DNA glycosylase) removes the uracil, leaving an abasic site that APE1/APE2 nicks. Nicks on both strands, aided by mismatch-repair proteins (MSH2/MSH6, EXO1), convert into staggered double-strand breaks (DSBs).
• 4. Synapsis and joining. The two DSBs — in Sμ and the acceptor S region — are joined by non-homologous end joining (NHEJ) (Ku70/Ku80, DNA-PKcs, XRCC4, DNA ligase IV), deleting the looped-out intervening DNA as a circle.

The result: the V(D)J exon now sits directly upstream of the new constant gene, and the cell secretes a switched isotype.

Key molecules and characteristic numbers

AID is the master enzyme — a 24 kDa, 198-amino-acid member of the APOBEC cytidine-deaminase family, encoded by AICDA. It is the single most important protein in CSR: without it, both class switching and somatic hypermutation fail completely. Crucially, AID also drives somatic hypermutation (affinity maturation) using the same C-to-U chemistry, but on the variable exon rather than switch regions — one enzyme, two outcomes decided by targeting and downstream repair.

• Switch regions: Sμ is ~4 kb; Sγ, Sε, Sα range from ~1 to 10 kb of tandem repeats rich in the AID hotspot motif WRC (W=A/T, R=A/G) — i.e., AGCT palindromes.
• Deleted DNA: switching from Cμ to a distal gene like Cα excises well over 100 kb, released as an episomal switch circle whose I-C transcript is a useful marker of ongoing CSR.
• Cytokine logic (mouse): IL-4 -> IgG1 and IgE; IFN-γ -> IgG2a; TGF-β -> IgA and IgG2b; IL-21 -> IgG1/IgG3. In humans, IL-4/IL-13 drive IgE.
• Fidelity: the switched cell keeps its original antigen specificity exactly — only the Fc changes.

How CSR is studied, observed, and regulated

Because CSR is a rare, timed event, immunologists study it with defined in vitro B-cell cultures: purified naive B cells stimulated with anti-CD40 (or LPS) plus a chosen cytokine will switch to a predictable isotype within 2-4 days, read out by flow cytometry for surface IgG1/IgE/IgA.

• Molecular readouts: digestion-circularization PCR and long-range PCR detect the recombined S-S junctions; RT-PCR for germline I-C and post-switch I-C transcripts reports promoter accessibility; sequencing switch junctions reveals the blunt or microhomology-mediated joins that betray NHEJ.
• Genetic dissection: knockout mice for Aicda, Ung, Msh2, or NHEJ factors each block or reroute CSR at a defined step, mapping the pathway.

Regulation operates at three levels: (1) which S region is transcribed, set by cytokine-driven germline transcription and enhancer/super-enhancer looping (the 3' regulatory region, 3'RR); (2) AID access and targeting, constrained by chromatin marks (H3K9ac, H3K4me3), Spt5, and the RNA exosome; and (3) tight control of AID abundance and localization, since misdirected AID is oncogenic. Epigenetic state of the locus is decisive — CSR is a textbook case of chromatin gating a DNA-recombination outcome.

How CSR compares to related genome-editing processes

CSR is one of three antibody-diversifying events, and it is easy to confuse them:

• V(D)J recombination assembles the variable exon in the bone marrow before antigen exposure. It uses RAG1/RAG2 recombinases cutting at recombination signal sequences (RSS) — a completely different enzymatic system. CSR, by contrast, edits the constant region after activation and needs AID, not RAG.
• Somatic hypermutation (SHM) shares the same initiator (AID deaminating C-to-U) but introduces point mutations into the variable exon to improve affinity, rather than causing a large deletion. CSR needs DSBs and NHEJ; SHM mostly needs error-prone repair (translesion polymerases like Pol η) and no deletion.
• Gene conversion (in birds and rabbits) uses AID plus homologous recombination to copy pseudogene segments into the variable region — a third fate for the same AID lesion.

The unifying insight, from Honjo's lab: a single deaminase creates a uracil lesion, and the choice of downstream repair pathway (NHEJ vs. error-prone synthesis vs. homologous recombination) dictates whether you get a switch, a point mutation, or a gene conversion.

Significance, disease relevance, and open questions

CSR is what makes vaccines and long-term immunity work. Neutralizing, opsonizing, and placenta-crossing IgG, mucosal IgA, and allergy/anti-parasite IgE all depend on it. Its failures and excesses map onto major disease:

• Hyper-IgM syndromes: loss-of-function mutations in AICDA cause autosomal-recessive HIGM2 — patients make abundant IgM but no IgG/IgA/IgE, with recurrent infections and giant germinal centers. Defects in CD40LG (X-linked HIGM1) or UNG produce related syndromes.
• Cancer: because AID makes DNA breaks, off-target activity drives the chromosomal translocations of B-cell lymphomas — e.g., MYC-IGH in Burkitt lymphoma and BCL6 rearrangements — making AID a double-edged sword.
• Allergy: excess IL-4-driven switching to IgE underlies atopic disease, a target of anti-IgE therapy (omalizumab).

Open questions: how AID is so precisely targeted to S regions yet spares the rest of the genome; how the two distant DSBs find each other in 3D (synapsis); why some junctions use alternative (microhomology-mediated) end joining; and whether AID targeting can be therapeutically restrained to prevent lymphoma without crippling immunity.

Antibody isotypes produced by class switching and their effector roles

Isotype	Constant gene / switch region	Induced primarily by	Main effector function
IgM	Cμ / Sμ (donor, no switch needed)	Default — first antibody made	Complement activation; pentamer, high avidity
IgG1-4	Cγ / Sγ	IFN-γ, IL-4, IL-21 (subclass-dependent)	Opsonization, ADCC, placental transfer, long-lived
IgA1-2	Cα / Sα	TGF-β, retinoic acid, IL-21 (+ APRIL/BAFF)	Mucosal immunity; secreted as dimer via pIgR
IgE	Cε / Sε	IL-4 and IL-13	Mast cell/basophil arming; allergy, anti-helminth
IgD	Cδ (mostly alternative splicing, not CSR)	Constitutive with IgM	B-cell receptor; basophil activation